argenx SE Investor Day Presentation Deck
Pemphigus Serves as Proof of Concept for Autoimmune
Blistering Diseases
Proof of Concept in Initial Indication...
Fast onset of action
SKIN BLISTERING DISEASES – AUTOANTIBODY DRIVEN
90% disease control after median time of 17 days
argenx
PEMPHIGUS
Significant responses
64% complete clinical remission after median 92 days
Corticosteroid sparing potential by using lower initial
doses of corticosteroids and rapid tapering
Favorable tolerability seen in data to date
BULLOUS PEMPHIGOID
...Before Expansion into Adjacent Indications
Autoantibodies initiate disease
Pathophysiology of blister formation more
heterogeneous
Larger yet more elderly, fragile population
Important to confirm efgartigimod profile in pemphigus
before expanding into other skin indications
44View entire presentation